Literature DB >> 8732134

[Nuclear cardiology study on effective ingredients of Astragalus membranaceus in treating heart failure].

H M Luo1, R H Dai, Y Li.   

Abstract

UNLABELLED: The experimental study has testified that among the various effective constituents gained from Astragalus membranaceus (AM) is the main component. Nineteen patients with heart congestive failure were treated with effective ingredient of AM, the astragaloside IV (XGA) injection.
RESULTS: After 2 weeks of treatment the symptoms of chest distress, dispnea in 15 patients was alleviated, their capability of exercise reinforced. Radionuclide ventriculography showed that left ventricular modelling improved, left ventricular end-diastolic volume diminished by 11.74 +/- 18.39 ml, left ventricular end-systolic volume by 9.35 +/- 18.01 ml, with statistical significance. HR slowed from 88.21 +/- 17.19 to 64.55 +/- 13.06 beats/min, P < 0.05; PER increased from 1.80 +/- 0.86 to 1.95 +/- 0.85 u/second, P < 0.05. Left ventricular EF, PFR increased also at some extent without statistical significance.
CONCLUSION: Effective ingredient of AM, XGA injection is efficient positive inotropic drug, and could improve the left ventricular modelling and ejection function in patients with congestive heart failure after continuous administration of XGA injection for two weeks.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8732134

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  7 in total

1.  Remission of CVB3-induced myocarditis with Astragaloside IV treatment requires A20 (TNFAIP3) up-regulation.

Authors:  Jun Gui; Ruizhen Chen; Wei Xu; Sidong Xiong
Journal:  J Cell Mol Med       Date:  2015-03-01       Impact factor: 5.310

2.  Global transcriptome analysis profiles metabolic pathways in traditional herb Astragalus membranaceus Bge. var. mongolicus (Bge.) Hsiao.

Authors:  Jing Chen; Xue-Ting Wu; Yi-Qin Xu; Yang Zhong; Yi-Xue Li; Jia-Kuan Chen; Xuan Li; Peng Nan
Journal:  BMC Genomics       Date:  2015-06-11       Impact factor: 3.969

3.  Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.

Authors:  Zeng Si Wang; Fei Xiong; Xiao Hang Xie; Dan Chen; Jian Hua Pan; Li Cheng
Journal:  BMC Nephrol       Date:  2015-03-31       Impact factor: 2.388

4.  EFFECT OF ASTRAGALOSIDE ON VITAMIN D-RECEPTOR EXPRESSION AFTER ENDOTHELIN-1-INDUCED CARDIOMYOCYTE INJURY.

Authors:  Chen Yunzhi; Chen Jiaxu; Gao Jie; Chai Yihui; Li Wen; Qin Zhong
Journal:  Afr J Tradit Complement Altern Med       Date:  2017-06-05

Review 5.  Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety.

Authors:  Abdullah Shaito; Duong Thi Bich Thuan; Hoa Thi Phu; Thi Hieu Dung Nguyen; Hiba Hasan; Sarah Halabi; Samar Abdelhady; Gheyath K Nasrallah; Ali H Eid; Gianfranco Pintus
Journal:  Front Pharmacol       Date:  2020-04-07       Impact factor: 5.810

6.  Effects of Astragaloside IV on heart failure in rats.

Authors:  Zhuanyou Zhao; Weiting Wang; Fang Wang; Kerui Zhao; Yingmei Han; Weiren Xu; Lida Tang
Journal:  Chin Med       Date:  2009-04-02       Impact factor: 5.455

7.  Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation.

Authors:  Yudi Zhang; Chunhe Tao; Chen Xuan; Junyan Jiang; Wenfu Cao
Journal:  Oxid Med Cell Longev       Date:  2020-08-12       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.